Dr. Paul Dempsey named top research executive for his work on Cynvenio’s LiquidBiopsy® system which can potentially transform cancer patient care.
Westlake Village, Calif., April 18, 2013 – Cynvenio Biosystems, Inc., a cancer diagnostics company focused on the molecular analysis of tumor biomarkers derived from whole blood, today announced that Dr. Paul Dempsey, its Chief Scientific Officer, has been named the top Healthcare Research Executive of 2013 by the Los Angeles Business Journal.
“Being recognized for the Healthcare Leadership Award is a tremendous honor, especially considering the quantity and quality of medical research that takes place in the Los Angeles area,” said Dempsey. “It’s extremely motivating.”
Dr. Dempsey was recognized for his efforts at Cynvenio to develop a new technique for the isolation of circulating tumor cells (CTCs) from whole blood. His work led to the creation of the LiquidBiopsy® platform and CLIA lab service that will be available to clinical oncologists, academic researchers and drug developers later this year. CTCs are increasingly being used in the development of companion diagnostics to better match patients with targeted therapies and to develop improved cancer drugs that can target individual patients’ cancer mutations.
“Dr. Dempsey and his team were the first to describe by next-generation sequencing very rare mutation-bearing CTC populations derived from whole blood, and to do so without error-inducing whole genome amplification,” said André de Fusco, president and CEO of Cynvenio. “His work inspires many in the field of genomics – collaborators and competitors alike - and will ultimately benefit all cancer patients.”
Before joining Cynvenio in 2009, Dempsey was an assistant researcher professor in the department of microbiology, immunology and molecular genetics at the University of California, Los Angeles. A virologist by training, Dempsey received his bachelor’s degree in microbiology and virology from the University of Warwick in Coventry in the United Kingdom and his Ph.D. from Johns Hopkins School of Medicine in Baltimore. He has published 20 scientific articles and abstracts and hold two issued patents in technologies designed to amplify the immunogenicity of vaccines.
About Cynvenio Biosystems, Inc.
Cynvenio Biosystems, Inc. is a molecular diagnostics company dedicated to the early detection and targeted treatment of cancer. Cynvenio has developed and deployed the LiquidBiopsy® system to enable realtime monitoring of tumor cell-associated mutations from a simple blood draw. This information can be used by physicians, academic centers, and drug developers to define treatment cycles for individual patients, efficiently select patients for drug trials and monitor patient response at any stage of disease.
LiquidBiopsy is a registered trademark of Cynvenio Biosystems, Inc.